PDCD1 and glioblastoma: Clinical studies have demonstrated that PD-L1–positive patients benefit significantly from combination therapy with PD-1 inhibitors (such as pembrolizumab) and CTLA4 inhibitors (such as ipilimumab), which markedly improves survival in recurrent glioblastoma (Duerinck et al., 2024).